2000
DOI: 10.1097/00020840-200002000-00014
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation and treatment of anosmia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
18
0
1

Year Published

2002
2002
2019
2019

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(19 citation statements)
references
References 6 publications
0
18
0
1
Order By: Relevance
“…At least 25% of all anosmias are caused by the presence of sinonasal disease 4–6 . In contrast with other major causes of smell impairments (head trauma, olfactory loss after infections of the upper respiratory tract), NP is treatable, and olfactory dysfunction is potentially reversible 7,8 . Olfactory loss in sinonasal disease typically occurs gradually over the course of years.…”
Section: Introductionmentioning
confidence: 99%
“…At least 25% of all anosmias are caused by the presence of sinonasal disease 4–6 . In contrast with other major causes of smell impairments (head trauma, olfactory loss after infections of the upper respiratory tract), NP is treatable, and olfactory dysfunction is potentially reversible 7,8 . Olfactory loss in sinonasal disease typically occurs gradually over the course of years.…”
Section: Introductionmentioning
confidence: 99%
“… 2,6–8 This difficult situation is underlined by the fact that, when “parosmia”/“troposmia” (distorted olfactory sensations elicited through odors) is present, 9,10 in some patients surgical removal of the olfactory epithelium may be considered as a cure. 11 …”
Section: Introductionmentioning
confidence: 99%
“…2,6 -8 This difficult situation is underlined by the fact that, when "parosmia"/"troposmia" (distorted olfactory sensations elicited through odors) is present, 9,10 in some patients surgical removal of the olfactory epithelium may be considered as a cure. 11 When searching for potential candidates for the pharmacological treatment of olfactory dysfunction we came across ␣-lipoic acid (aLA), which is used in the treatment of diabetic neuropathy. [12][13][14][15] The effect of aLA is well described both in experimental animals and in humans (for review see Packer et al 16 ).…”
Section: Introductionmentioning
confidence: 99%
“…4). [11][12][13][14] In addition, respiratory problems may prevent airflow to the olfactory cleft, thus producing olfactory loss. More recently, localized inflammation of the olfactory cleft with consecutive thickening of the mucosa is described as a possible cause of olfactory loss.…”
Section: Olfactory Nervesmentioning
confidence: 99%